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Abstract: A de novo somatic mutation in the mammalian target of rapamycin (MTOR) has previously been described in one patient with
hemimegalencephaly and epilepsy. Here, we present a case of a young girl with megalencephaly and intractable seizures who was found
to have an MTOR mutation in multiple cell lineages (p.Cys1483Phe) and, therefore, presumed to be of germline origin. The mutation
was detected in peripheral blood DNA by exome sequencing of the patient and her parents, substantiating the utility of this approach for
detection of clinically relevant de novo variations.
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Introduction

Seizure disorders are common. About 4% of individuals will be diagnosed with epilepsy during their
lifetime.1 Approximately 70% of seizures are currently classified as either idiopathic or cryptogenic,
although an underlying genetic etiology might be
suspected.1,2 In the majority of these individuals,
the pattern of inheritance is not consistent with a
simple, monogenic Mendelian disorder. However,
when accompanied by other clinical findings, such
as dysmorphic features, the probability of identifying
an underlying genetic cause is greater.1 The advent
of exome sequencing technologies has made it possible to evaluate the candidacy of hundreds of potential genetic diagnoses simultaneously in patients with
previously molecularly uncharacterized seizure disorders, as well as implicating genes that might not previously have been associated with seizure disorders.3–5
Furthermore, exome sequencing of an affected patient
and unaffected parents (trios), together with bioinformatic tools, has recently made it possible to identify
de novo mutations that are causative of dominant
genetic disorders.6
It has long been recognized that dominant mutations in PTEN (phosphate and tensin homolog, OMIM
601728), TSC1 (tuberous sclerosis 1, OMIM 605284),
and TSC2 (tuberous sclerosis 2, OMIM 613254) result
in overgrowth syndromes (OMIM 158350, 153480,
191100, 191092) of which seizures are a component. More recently, de novo somatic mutations in
MTOR (mammalian target of rapamycin, OMIM
601231) and germline and postzygotic mutations in
PIK3CA and AKT3 (phosphatidylinositol 3-kinaseAKT pathway) have been implicated in hemimegalencephaly (OMIM 605201).7,8 These gene products
are all critical components of the PI3K-AKT3-mTOR
pathway. This pathway is a critical intracellular signaling pathway that integrates input from upstream
pathways and regulates, among other things, cell
growth and proliferation, apoptosis, protein synthesis, and transcription.9 Furthermore, hyperactivation
of this pathway is epileptogenic and associated with
neuropathologic abnormalities such as focal cortical dysplasia and hemimegalencephaly.10 Altered
mTOR signaling provides the basis for what are now
called “TORopathies,” conditions that are characterized by intractable seizures, focal cortical dysplasia,
and hemimegalencephaly.9,10 The majority of these
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c onditions (tuberous sclerosis complex (TSC) OMIM
191100, 191092, PTEN hamartoma tumor syndrome
601728) are inherited in an autosomal dominant fashion. As noted above, several have also been found
to occur postzygotically and thus result in tissue
mosaicism.7,8 To date, there has only been one clinical report of a mutation in MTOR that was identified
as a de novo somatic event present in affected tissue
but not in blood that resulted in hemimegalencephaly
and epilepsy.8 We present the first case of a young girl
with megalencephaly and intractable seizures who
was found to have a mutation in MTOR in multiple
cell lineages and, therefore, presumed to be of germline origin. This study also demonstrates the critical
role that newer technologies will play in the ability to
make medical diagnoses and potentially affect management in rare genetic disorders.

Case Study

Our patient was a female born at 35 weeks estimated
gestational age. She was the product of a second pregnancy to a 26-year-old gravida 2, para 10 mother and
28-year-old father. The pregnancy was complicated
by maternal hypothyroidism and prematurity related
to preeclampsia diagnosed at estimated gestational
age 34 weeks. Fetal movements were described as
active, and frequent fetal hiccups were noted. Maternal serum screening and prenatal diagnostic testing
were declined. A cesarean section was performed
due to frank breech presentation. Birth weight was
2892 grams (84% for gestational age), birth length
was 49.5 cm (90% for gestational age), and macrocephaly was noted with an occipitofrontal circumference (OFC) of 39.0 cm (50% for a 2.5 month old).
There was some difficulty with delivery secondary to
the infant’s large head and supplemental oxygen was
required for a short time perinatally. The infant was
found to be hypoglycemic and thrombocytopenic.
She remained in the neonatal intensive care unit for
19 days due to poor suck and swallow. A brain magnetic resonance imaging (MRI) scan obtained during
that hospitalization revealed callosal dysgenesis and
mild dilatation of the posterior horns of the lateral ventricles. Expanded newborn screening was normal.
Seizures were first noted during a desaturation
event when the infant was admitted to an outside hospital for bronchiolitis. Seizures, described as apnea
episodes that were initially not associated with motor
Journal of Genomes and Exomes 2013:2
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involvement, were noted to be quite frequent, lasting
from 10 seconds to 2 minutes. The patient was admitted to our institution at 2 months of age secondary
to intractable seizures. The electroencephalogram
(EEG) at that time was remarkable for electrographical seizures consisting of a buildup of high voltage
(0.5–1.5 Hz) spike and slow wave activity with evolution to faster 2 to 3 Hz spike and slow wave discharges in the left occipto-temporo-parietal region.
This was followed by superimposed high voltage 1.5
to 3 Hz focal slowing. There was no clear correlation between clinical findings and EEG changes.The
abnormal EEG was felt to be consistent with epileptiform activity along with a focal disturbance in cerebral function over the left occipito-temporo-parietal
region. Treatment with antiepileptic medication
(oxcarbazepine, and leviteracitam) was attempted but
was unsuccessful. The infant was seen by a geneticist
for an initial evaluation at that time due to concerns
about a possible inborn error of metabolism. She was
found to be at the 70th percentile for length and the
21st percentile for weight. Head circumference was
found to be at the 50th percentile for a 14 month old
(Fig. 1). She had dysmorphic features (Fig. 2), including a large anterior fontanelle, frontal bossing, midface
hypoplasia, and a small chin. She was hyperteloric
with downslanting palpebral fissures and a depressed

nasal bridge. Brows were full and widely spaced.
Eyelashes were thick. No cataracts, corneal clouding, or colobomata were identified. Ears were lowset but with otherwise normal architecture. The nose
was short and upturned. Philtrum was smooth and the
upper lip was thin. The mouth was held slightly open,
making the tongue appear prominent. The neck was
short without folds or remnants. The thoracic cage
appeared narrow. Cardiac and lung exams were normal. There was a sacral cleft but no scoliosis. There
was an easily reducible umbilical hernia. There was
no organomegaly. External genitalia were normal
for age and the anus was nondisplaced. Extremities
appeared rhizomelic and hands had a trident appearance with short proximal phalanges. Hips were lax
but nondislocatable, and skin folds were asymmetric.
There were no unusual markings on the skin. She was
mildly hypotonic with poor head control. Deep tendon reflexes were present and symmetric. No unusual
movements were noted.
Extensive metabolic and genetic testing was negative. A karyotype and CGH microarray were performed and demonstrated a normal 46, XX karyotype.
A skeletal survey was unremarkable, and FGFR3
gene sequencing was negative, ruling out achondroplasia. A basic metabolic panel was essentially normal
as were liver function tests, although indirect bilirubin

Figure 1. Occipitofrontal circumference over time (World Health Organization growth chart) demonstrating rapid head growth and macrocephaly.
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and slow waves involving both cerebral hemispheres
along with signs of severe epileptic encephalopathy.
At age 13 months, while on polytherapy with antiseizure medication (leviteracitam, zonisamide, phenobarbital, and lacusamide), the ketogenic diet with
a 3.5:1 ratio was initiated resulting in a decrease in
frequency of seizure activity from 4 to 5 seizures per
week to 1 less intense seizure per week that lasted
anywhere from 20 seconds to 3 minutes. At this time,
PTEN sequencing was ordered and was negative.
Given the negative workup and parental desire to
limit venous blood draws, consents were obtained for
the patient and her parents to be enrolled in an institutional review board (IRB)-reviewed exome sequencing study at Children’s Mercy Hospital, Kansas City,
MO. She contracted respiratory syncytial virus pneumonia at 19 months of age and expired secondary to
hypoxic respiratory failure.

Methods
Consent
Figure 2. Clinical features of the proband over time. A. 3 months of age.
B. 17 months of age. C and D. 19 months of age. Note macrocephaly,
frontal bossing, prominent forehead, downslanting palpebral fissures,
long eyelashes, short upturned nose, umbilical hernia, and myopathic
appearance.

was slightly elevated at 1.5 mg/dL (0.0–1.2 mg/dL).
Very long chain fatty acids were normal, ruling out
Zellweger spectrum disorders. An acylcarnitine profile was also normal consistent with the reported normal state newborn screening results. Mucolipidosis
II/III was ruled out with normal alpha-glucuronidase,
alpha-L-fucosidase and beta-hexosaminidase activities. Additionally, a plasma amino acid profile was
unremarkable, as were plasma ammonia, plasma
lactic acid, and plasma pyruvic acid levels. Notably,
there were no elevations of glutamine, alanine, or glycine, and the lactic to pyruvic acid ratio was 12.2 (normal  20), making a mitochondrial disorder unlikely.
The child was discharged and followed closely in
genetics and neurology clinics. While her length and
weight remained on the normal growth curves for age,
she had rapid growth of her head with head circumferences consistently above the 95th percentile for age
(Fig. 2). A repeat EEG at 8 months of age revealed
worsening of seizures with multifocal spike, sharp
66

The study was approved by the Institutional Review
Board (IRB) of Children’s Mercy Hospital (CMH).
Informed written consent was obtained from both
parents.

Clinicopathologic correlation
and interpretation

The features of the patient’s disease were mapped to
likely candidate genes with SSAGA (Symptom and
Sign Assisted Genome Analysis).5 The symptoms
of macrocephaly and epilepsy nominated 44 and
174 genes, respectively (Supplement Table 1). A
total of 198 genes were nominated for initial genetic
analysis, 20 of which were nominated by both symptoms. Blood samples were obtained from the affected
patient and her parents.

Genome and targeted exome
sequencing

DNA isolated from peripheral blood cells was prepared for exome enrichment and next generation
sequencing. Briefly, indexed Illumina sequencing
libraries were created using the KAPA Biosystems
library preparation kit (KAPA Biosystems, Woburn,
MA) following manufacturers recommended protocols and 8 cycles of PCR amplification. Exome
enrichment was conducted with the Illumina TruSeq
Journal of Genomes and Exomes 2013:2
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Exome v1 kit, which targets 62.2 megabases, 20,794
genes, and 201,121 exons, following manufacturers protocols (Illumina, San Diego, CA).11 Successful enrichment was verified by qPCR of 4 targeted
loci and 2 non targeted loci of the sequencing library
pre- and post-enrichment prior to sequencing. Quantitation of enriched sequencing libraries was assessed
by real-time PCR.11 Samples were sequenced with
2 × 100 base pair sequencing on an Illumina HiSeq
2000 instrument with TruSeq v3 reagents.

Sequence analysis

Gapped alignment to the reference nuclear and mitochondrial genome sequences (Hg19 and GRCH37
[NC_012920.1], respectively) was performed with
the Genomic Short-read Nucleotide Alignment Program (GSNAP),12 and the Genome Analysis Toolkit (GATK)13 was applied.5 Variants were called
according to the GATK’s Best Practices for Variant
Detection v3. Briefly, original GSNAP alignments
were locally realigned around candidate indels, then
duplicate reads were marked and, finally, alignment
base quality scores were recalibrated. Using the postprocessed alignments, SNP and indels were initially
called with the Unified Genotyper then separately filtered. SNPs were additionally processed through the
GATK’s variant quality score recalibration workflow
which builds an adaptive error model using known
variant sites and then applies this model to minimize false positive calls. Nucleotide variants were
genotyped, annotated for functional significance with
RUNEs, and analyzed as described.5

Results

Exome sequencing was performed to a depth of at
least 100-fold in the patient (CMH000096), her
mother (CMH000097), and her father (CMH00098),
resulting in greater than 94% of targeted nucleotides
receiving 10-fold or greater coverage (Supplement
Table 2). A total of 133,294, 135,191, and 140,924
nucleotide variants were identified in the patient,
her mother, and her father respectively, of which
2583 were annotated as potentially deleterious in the
proband (as assessed by a deleteriousness classification of 1–3 by the Rapid Understanding of Nucleotide
variant Effect Software (RUNES v1.0) (Supplement
Table 2).5 A total of 21 classification 1–3 variants
were found in the 198 genes nominated by SSAGA
Journal of Genomes and Exomes 2013:2

(Supplement Table 3). Limiting these variants to only
those with an allele frequency of 1% or less resulted
in only 2 variants in 2 genes, but neither were in
genes associated with a phenotype consistent with
this patient’s presentation or of the type consistent
with recessive or dominant inheritance. Expanding
the variants to those located in genes other than those
nominated by SSAGA with an allele frequency of
1% or less resulted in a total of 467 variants. Of these
variants, 8 had previously been annotated as disease
causing, and 25 were of the type likely to disrupt gene
function; however, after expert review, none of these
variants were considered likely to be associated with
the clinical phenotype in this patient. Applying a recessive inheritance pattern to the 467 variants yielded
34 variants in 25 genes. Six genes had homozygous
variants (Supplement Table 4), and 17 genes had
2 or more heterozygous variants consistent with an
autosomal recessive inheritance pattern (Supplement
Table 4). None of these genes were associated with
phenotypes consistent with the clinical history. The
exome of the proband was then examined for de novo
mutations by limiting the analysis to variants not
detected in either parent, which yielded 3 genes and
variants (Supplement Table 4). Of these, the proband
had one heterozygous de novo variant, c.4448G  T
(p.Cys1483Phe) in MTOR that was phenotypically
relevant. The variant was found in 20 of 43 reads
(47%) in the patient and not seen in 56 or 57 reads
covering that nucleotide position in her mother or
father, respectively (Fig. 3). Subsequently, this mutation was confirmed by capillary sequencing to be
heterozygous (present in approximately 50% in DNA
from peripheral blood leukocytes, a buccal smear,
and urine sediment cells from the patient), suggesting
that the mutation is likely to be pancellular and germline in nature. Capillary sequencing did not identify
this variant in peripheral blood DNA or buccal DNA
of either parent. A change at this nucleotide position
has been reported as a de novo somatic mutation in
a patient with hemimegalencephaly wherein varying mutation loads were observed in different brain
sections and absent in the blood.8 While a change
from a cysteine (TGT) to a tyrosine (TAT) has been
reported,8 a transversion was identified in our patient
that results in a change from a cysteine (TGT) to a
phenylalanine (TTT). The cysteine residue is highly
conserved among species (Supplement Fig. 1), and
67
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Figure 3. A. Next generation sequencing results viewed in the Integrative Genome Viewer30 of de novo heterozygous variant c.4448 G  T (p.Cys1483Phe)
in the MTOR gene, found in 20 of 43 reads (47%) in the proband (CMH000096) and absent in the father (CMH000097) and the mother (CMH000098).
B. Sanger sequencing comparison showing heterozygosity for the c.4448 G  T (p.Cys1483Phe) variant in 3 different sample types isolated from the
proband. DNA from peripheral blood, urine sediment, and buccal swabs.

the change is likely to be pathogenic. It has been proposed that a change at this residue results in a gain of
function in mTOR.8

Discussion

The MTOR pathway is highly regulated and critical for cell survival and apoptosis (Fig. 4). MTOR

is a key regulator of protein synthesis, cell growth,
and cell proliferation. It also plays a role in synaptic
plasticity.9,10 It is negatively regulated by hamartin and
tuberin, the products of TSC1 and TSC2, respectively.
Mutations in either of these genes result in tuberous
sclerosis (TS), a condition that presents with hamartomas and epilepsy. TSC1 and TSC2 are negatively

Figure 4. Simplified PI3K/AKT/mTOR pathway: stimulatory effects (
) ; Inhibitory effects ( ) ; PIK3-phosphoinositide 3-kinase; PTEN-phosphatase and
tensin homolog; LKβ1-liver kinase β1; Akt-B protein kinase B; AMPK-AMP-activated protein kinase; Tsc1-tuberous sclerosis 1; Tsc2-tuberous sclerosis 2;
mTOR-mammalian target of rapamycin; S6-ribosomal protein S6.
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regulated by PI3K and AKT, both of which have
been implicated in hemimegalencephaly syndromes,
which are also complicated by epilepsy. This pathway
is also regulated by PTEN, mutations in which result
in overgrowth and epilepsy. It has been demonstrated
in a mouse model that selective deletion of Pten in
postnatally generated granule cells was sufficient to
cause epilepsy.14 Since no tumors were found in these
animals, it was postulated that the deletion of Pten
resulted in activation of Mtor and that this activation
was epileptogenic. The exact pathologic mechanism
of epileptogenesis remains unclear. It is known that
MTOR negatively regulates autophagy in response
to growth factors, nutritional status and stress
responses.15 It has been observed in mouse embryonic
fibroblasts deleted for Tsc2 that autophagocytic activity is downregulated.16,17 McMahon et al have subsequently demonstrated that Tsc1 and Pten knockout
mice have impaired autophagy along with recurrent
seizures.18 This was correlated with increased phosphorylation of S6 in the mouse cortex and hippocampus, an indirect marker of Mtor hyperactivation. This
finding was recapitulated in samples from brains of
human patients with tuberous sclerosis. In addition,
seizures were much more severe in mice with deletion of Tsc1 and Pten than in mice deleted for Atg7,
which is directly involved in inhibition of autophagy
but is not involved in regulation of Mtor. Thus, it
would appear that impaired autophagy in neurons is
directly related to unregulated expression of MTOR
and that this plays some role in epilepsy.
Medical interventions that modulate the PI3KAKT3-mTOR pathway may prove effective in the
management of seizures.19 The ketogenic diet has
been used successfully for the treatment of intractable
seizures by both anticonvulsant effect and by preventing, at least in an animal model of status epilepticus,
mossy fiber sprouting.20,21 McDaniel et al demonstrated that the ketogenic diet manifests its effects
via inhibition of the MTOR pathway as evidenced by
decreased phosphorylation and expression of pS6 and
pAkt in the liver and hippocampus of rats maintained
on the diet.22 This also raises the tantalizing possibility
that treatment with rapamycin, which inhibits MTOR
activity, might be useful in the management of seizure
disorders. The effectiveness of rapamycin has been
demonstrated in several animal models of chronic
epilepsy,23–26 although its effectiveness as an acute
Journal of Genomes and Exomes 2013:2

treatment has not been demonstrated.27 To date, there
has been one published case of the successful use of
rapamycin in the management of seizures associated
with tuberous sclerosis28 as well as a recent report
of efficacy in prevention of seizures associated with
polyhydramnios, megalencephaly, and symptomatic
epilepsy syndrome. The latter syndrome results from
deficiency of pseudokinase, an upstream inhibitor of
MTOR1.29 Thus it is conceivable that treatment of our
patient with rapamycin might have been effective.
While clinical trials in the use of rapamycin in TS are
currently underway, since there is only one report of
a gain of function mutation in MTOR, the efficacy of
rapamycin under such conditions has not been tested.
While de novo germline mutations in AKT3,
PIK3R2, and PIK3CA in megalencephaly syndromes
have been observed,8 this report identified only a single case of hemimegalencephaly associated with a de
novo somatic cell mutation in MTOR from a cysteine
to a tyrosine moiety at residue 1483. This mutation
was identified in brain cells after hemispheric resection but was not found in blood leukocytes. It was
postulated that this mutation, which changes the same
cysteine residue observed in our patient, leads to a
gain of function of MTOR. Both phenylalanine and
it’s derivative tyrosine replace an uncharged polar sulfur-containing side chain with a bulky nonpolar side
chain and would be expected to disrupt protein conformation. Our case represents the first case wherein a
mutation in MTOR in a patient with symmetric megalencephaly and seizures has been identified in blood.
Furthermore, the mutation was found to be present
in both buccal and urine sediment cells, suggesting
that the mutation in this child is pancellular. It is also
notable that this child, for whom control of seizures
was incomplete and required polypharmaceutical
intervention, had a tempered response to the ketogenic diet. Since the ketogenic diet is felt to downregulate expression of MTOR, this suggests that at some
level either increased expression or increased activity
of MTOR is playing a role in epileptogenesis. It may
be that provision of the ketogenic diet was not completely successful because downregulation of MTOR
gene expression does not completely counteract the
possible gain of function resulting from the mutation.
The natural history of individuals with mutations in
MTOR is unknown. Axial skeletal overgrowth is not
affected by mutations in MTOR, but megalencephaly
69
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is clearly a finding. It may be that treatment with
rapamycin might have resulted in decreasing the rate
of rapid head growth in this patient. It is also possible,
given the role of MTOR in tumorigenesis, that this
child, had she survived, been at risk for solid tumor
development and that treatment with rapamycin might
have reduced this risk. Just prior to initiation of treatment with rapamycin in an attempt to improve seizure
control, the patient developed a respiratory infection
requiring hospitalization. She experienced a massive
generalized seizure that resulted in obtundation. The
difficult decision to remove ventilatory support was
made, and the patient expired; thus, we are unable to
say what effect treatment with rapamycin may have
had on her clinical course.

Conclusion

Despite this unfortunate outcome, this case study
emphasizes the role that new technologies such as
exome and whole genome sequencing will play in
the future of clinical care and development of personalized treatments. It is interesting to postulate what
the clinical course might have been had a mutation
in MTOR been identified in the neonatal period with
subsequent early treatment with rapamycin.
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